{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:39:18Z","timestamp":1791128358655,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jaad.2014.02.035","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T07:51:30Z","timestamp":1398325890000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["Ipilimumab in patients with cancer and the management of dermatologic adverse events"],"prefix":"10.1016","volume":"71","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus J.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.02.035_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"Hoos","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.02.035_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.02.035_bib4","series-title":"Yervoy (ipilimumab) [prescribing information]","year":"2011"},{"key":"10.1016\/j.jaad.2014.02.035_bib5","series-title":"Yervoy (ipilimumab) [product information]","year":"2011"},{"key":"10.1016\/j.jaad.2014.02.035_bib6","series-title":"Australian public assessment report for ipilimumab","year":"2011"},{"key":"10.1016\/j.jaad.2014.02.035_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab; case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2014.02.035_bib8","series-title":"Yervoy (ipilimumab) [US prescribing information: risk evaluation and mitigation strategy]","year":"2011"},{"key":"10.1016\/j.jaad.2014.02.035_bib9","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare\u00a0side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl","key":"10.1016\/j.jaad.2014.02.035_bib10","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1200\/jco.2011.29.15_suppl.8583","article-title":"Ipilimumab safety profile: summary of\u00a0findings from completed trials in advanced melanoma [abstract]","volume":"29","author":"Ibrahim","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2014.02.035_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2014.02.035_bib13","first-page":"588","article-title":"Technology evaluation: ipilimumab, Medarex\/Bristol-Myers Squibb","volume":"7","author":"Morse","year":"2005","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jaad.2014.02.035_bib14","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.02.035_bib15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2014.02.035_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with previously treated, advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib17","first-page":"5591","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in\u00a0patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.jaad.2014.02.035_bib18","first-page":"1712","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm, phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib19","unstructured":"Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et\u00a0al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase 2 trials [abstract P-20]. Presented at: Perspectives in Melanoma XV; September 16-17, 2011; New York, NY."},{"key":"10.1016\/j.jaad.2014.02.035_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","article-title":"Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control","volume":"19","author":"Robert","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.02.035_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2014.02.035_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility,\u00a0and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2014.02.035_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2230.2011.04117.x","article-title":"Higher severity grade of erlotinib-induced rash is associated with lower skin phototype","volume":"36","author":"Luu","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2014.02.035_bib24","first-page":"1","article-title":"Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a\u00a0dermatology-oncology perspective","volume":"12","author":"Lacouture","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaad.2014.02.035_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.02.035_bib26","first-page":"1280","article-title":"Ipilimumab: a promising immunotherapy for melanoma","volume":"24","author":"Thumar","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2014.02.035_bib27","doi-asserted-by":"crossref","first-page":"182157","DOI":"10.1155\/2012\/182157","article-title":"Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?","volume":"2012","author":"Pi\u00e9rard","year":"2012","journal-title":"Dermatol Res Pract"},{"issue":"Suppl","key":"10.1016\/j.jaad.2014.02.035_bib28","doi-asserted-by":"crossref","first-page":"LBA5","DOI":"10.1200\/jco.2011.29.18_suppl.lba5","article-title":"Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) vs DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma [abstract]","volume":"29","author":"Wolchok","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2340\/00015555-0280","article-title":"Nocturnal itch: why do we itch at night?","volume":"87","author":"Patel","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.02.035_bib30","unstructured":"Final study report for CA184007. Available from: URL:http:\/\/www.ctr.bms.com\/pdf\/\/CA184-007%20ST.pdf. Accessed March 25, 2014."},{"key":"10.1016\/j.jaad.2014.02.035_bib31","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of skin rash associated with ipilimumab in patients with cancer: a systematic review of literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2014.02.035_bib32","first-page":"8523","article-title":"Phase II trial of ipilimumab monotherapy in\u00a0melanoma patients with brain metastases [abstract]","volume":"28","author":"Lawrence","year":"2010","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2014.02.035_bib33","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/jco.2010.28.15_suppl.7531","article-title":"Phase II trial of ipilimumab and paclitaxel\/carboplatin in first-line stage IIIb\/IV non-small cell lung cancer","volume":"28","author":"Lynch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and\u00a0toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2014.02.035_bib35","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc\u00a0Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2014.02.035_bib36","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T-lymphocyte antigen-4","volume":"25","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib37","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2014.02.035_bib38","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/1078-0432.CCR-08-2424","article-title":"Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4","volume":"15","author":"Klein","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.02.035_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2014.02.035_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-3083.2010.03763.x","article-title":"Immunophenotyping of inflammatory cells in subacute prurigo","volume":"25","author":"Gambichler","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.02.035_bib42","unstructured":"Lebb\u00e9 C, O'Day SJ, Chiarion Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et\u00a0al. Analysis of the onset and resolution of\u00a0immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma [abstract O-01]. Presented at: Perspectives in Melanoma XII; October 2-4, 2008; The Hague, The Netherlands."},{"key":"10.1016\/j.jaad.2014.02.035_bib43","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.02.035_bib44","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in\u00a0patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.02.035_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5021\/ad.2011.23.1.1","article-title":"Chronic pruritus: clinics and treatment","volume":"23","author":"Grundmann","year":"2011","journal-title":"Ann Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214011529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214011529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:31:41Z","timestamp":1759271501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214011529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0190962214011529"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.02.035","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}